Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD

A. Lipson, David; Barnhart, Frank; Brealey, Noushin; Brooks, Jean; J. Criner, Gerard; C. Day, Nicola; T. Dransfield, Mark; Halpin, David; K. Han, MeiLan; Jones, Christine; Kilbride, Sally; Lange, Peter; A. Lomas, David; J. Martínez, Fernando; Singh, Dave; Tabberer, Maggie; A. Wise, Robert; Pascoe, Steven

doi:10.1056/nejmoa1713901

Public

Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD

Published in New England Journal of Medicine • Apr 18, 2018

Authors:

David A. Lipson

Frank Barnhart

Noushin Brealey

Abstract

BACKGROUND: -agonist (LABA), as compared with dual therapy (either inhaled glucocorticoid-LABA or LAMA-LABA), are uncertain. METHODS: In this randomized trial involving 10,355 patients with COPD, we compared 52 weeks of a once-daily combination of fluticasone furoate (an inhaled glucocorticoid) at a...

Subject

Lama

Muscarinic antagonist

Inhaler

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!